Literature DB >> 11830307

A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time.

A Hliniak1, B Gwiazdowska, Z Szutkowski, E Kraszewska, P Kukolowicz, A Jarzabski, B Sochacka, M Mazurkiewicz, K Paprota, W Oliskiewicz, O Zadrozna, P Milecki, M Kubiak, L Czopkiewicz, M Jagas, S Góźdź, A Wieczorek, A Woytowicz, B Cisowska, H Magdziarz, S Nowakowski, W Kośniewski, I Laskosz, A Serafin, E Gradoń.   

Abstract

BACKGROUND AND
PURPOSE: To compare in a phase III study the loco-regional control, disease-free survival and overall survival induced by an accelerated regimen (AF) as compared with conventional regimen (CF) and to analyze the early and late post-radiation morbidity in both arms.
MATERIALS AND METHODS: Patients with age < or = 75, WHO 0-1, suitable for a radical course of radiotherapy T1-T3, N0, M0, stage of glottic and supraglottic laryngeal cancer were randomized to either CF: 66Gy given in 33 fractions over 45 days or AF: 66Gy given in 33 fractions over 38 days (2 fractions every Thursday). A total of 395 patients were included from 05.1995 to 12.1998.
RESULTS: Early toxicity: At the end of radiotherapy patients treated with AF complained for more severe reactions than patients treated with CF. In 8 weeks after treatment completion patients treated with AF complained only for more severe pain on swallowing (P=0.027). In 4 months after treatment completion all types of toxicity except for skin teleangiectasia (P=0.001) were similar in the two groups. Loco-regional control: comparison between CF and AF showed no difference in terms of loco-regional control (P=0.37).
CONCLUSIONS: The improvement in AF in terms of loco-regional control is estimated to be 3-5% in comparison with conventional regimen and is not significant. The intensity of reactions after 4 months was similar in both arms, what suggests the possibility of further shortening of the overall time by few days or enhancing the total dose within the limits of acceptable morbidity.

Entities:  

Mesh:

Year:  2002        PMID: 11830307     DOI: 10.1016/s0167-8140(01)00494-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

Review 2.  Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review.

Authors:  Xiao-Ning Luo; Liang-Si Chen; Si-Yi Zhang; Zhong-Ming Lu; Yan Huang
Journal:  Radiol Med       Date:  2015-05-16       Impact factor: 3.469

3.  Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

Authors:  Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-20

4.  Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).

Authors:  Andy Trotti; Qiang Zhang; Søren M Bentzen; Bahman Emami; M Elizabeth Hammond; Christopher U Jones; William H Morrison; Stephen M Sagar; John A Ridge; Karen K Fu; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

5.  Altered fractionation outcomes for hypoxic head and neck cancer using the HYP-RT Monte Carlo model.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

Review 6.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

Review 7.  Hyperfractionated or accelerated radiotherapy for head and neck cancer.

Authors:  Bertrand Baujat; Jean Bourhis; Pierre Blanchard; Jens Overgaard; Kian K Ang; Michelle Saunders; Aurélie Le Maître; Jacques Bernier; Jean Claude Horiot; Emilie Maillard; Thomas F Pajak; Michael G Poulsen; Abderrahmane Bourredjem; Brian O'Sullivan; Werner Dobrowsky; Hliniak Andrzej; Krzystof Skladowski; John H Hay; Luiz Hj Pinto; Karen K Fu; Carlo Fallai; Richard Sylvester; Jean Pierre Pignon
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

8.  Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis.

Authors:  Yingyu Liu; Changgui Kou; Wei Bai; Xinyu Liu; Yan Song; Lili Zhang; Mohan Wang; Yangyu Zhang; Yueyue You; Yue Yin; Xin Jiang; Ying Xin
Journal:  Onco Targets Ther       Date:  2018-09-04       Impact factor: 4.147

Review 9.  Radiotherapy for laryngeal cancer-technical aspects and alternate fractionation.

Authors:  Hideya Yamazaki; Gen Suzuki; Satoaki Nakamura; Ken Yoshida; Koji Konishi; Teruki Teshima; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.